"Prototype Drug Uses Novel Mechanism To Treat Lung Cancers"
Cells are constantly turning proteins on and off via molecular switches-phosphate molecules-that have become common drug targets. Researchers collaborated to screen a series of drug-like molecules for their ability to reactivate PP2A in lung cancer cells and prevent lung cancer tumors in mice. The prototype drug molecules were created from FDA-approved medications by Michael Ohlmeyer, PhD, an associate professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai.
- Michael Ohlmeyer, PhD, Associate Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai
Learn more
Mount Sinai Study May Help Cancer Patients Keep Their Bladder
Feb 19, 2026 View All Press Releases
Mount Sinai Scientists Create AI-Powered Tool to Improve Cancer Tissue Analysis
Aug 25, 2025 View All Press Releases